Print ISSN:-2394-2789
Online ISSN:-2394-2797
CODEN : IJPCN9
Original Article
Author Details :
Volume : 2, Issue : 1, Year : 2015
Article Page : 28-33
Abstract
A new simple, precise, accurate and selective RP-HPLC method has been developed and validated for estimation of salmeterol xinafoate in pharmaceutical formulation. The method was carried out on a Qualisil RP C-18 (250 mm x 4.6 mm, 5 ?m) column with a mobile phase consisting of buffer: acetonitrile: methanol (45:25:30 v/v/v), pH adjusted to 6 with diammonium hydrogen orthophosphate and flow rate of 0.5 mL/min. Detection was carried out at 250 nm. The retention time for salmeterol xinafoate was found to be 7.41 min. The salmeterol xinafoate followed linearity in the concentration range of 1- 6 ?g/mL (r2= 0.9984). The amount of the drug estimated by proposed method was found to be in good agreement with label claim. The developed method was validated for sensitivity, accuracy, precision, ruggedness and robustness. The LOD and LOQ were found to be 0.10 and 0.29 ?g. Salmeterol xinafoate was subjected to acid and alkali hydrolysis, oxidation and thermal degradation. The drug undergoes degradation under acidic, basic, oxidation and thermal conditions. This indicates that the drug is susceptible to acid, base, oxidation and thermal conditions. The degraded product was well resolved from the pure drug with significantly different Retention Time. The proposed method can be used for routine analysis of salmeterol xinafoate in bulk drug and pharmaceutical formulation.
How to cite : Jain* P S, Gorle A P, Patil S S, Chavan R S, Bari P R, Surana S J, Stability-indicating RP-HPLC Method for Estimation of Salmeterol xinafoate in Bulk and in Pharmaceutical Formulation. Int J Pharm Chem Anal 2015;2(1):28-33
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.